Illumina Inc Asset Resilience Ratio
Illumina Inc asset resilience ratio. Illumina Inc (ILMN) has an Asset Resilience Ratio of 24.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ILMN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Illumina Inc (1999–2025)
Asset resilience ratio of Illumina Inc from 1999 to 2025. This chart shows how Illumina Inc's Asset Resilience Ratio has changed over time. Read ILMN total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Illumina Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Illumina Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.42 Billion | 21.34% |
| Short-term Investments | $215.00 Million | 3.24% |
| Total Liquid Assets | $1.63 Billion | 24.58% |
Asset Resilience Insights
- Good Liquidity Position: Illumina Inc maintains a healthy 24.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Illumina Inc Industry Peers by Asset Resilience Ratio
Compare Illumina Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Illumina Inc Asset Resilience Ratio by Year (1999–2025)
Illumina Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Illumina Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.58% | $1.63 Billion | $6.64 Billion | +5.22pp |
| 2024-12-31 | 19.36% | $1.22 Billion | $6.30 Billion | +8.93pp |
| 2023-12-31 | 10.42% | $1.05 Billion | $10.11 Billion | -6.20pp |
| 2022-12-31 | 16.63% | $2.04 Billion | $12.25 Billion | +7.83pp |
| 2021-12-31 | 8.80% | $1.34 Billion | $15.22 Billion | -36.98pp |
| 2020-12-31 | 45.77% | $3.47 Billion | $7.58 Billion | +27.02pp |
| 2019-12-31 | 18.75% | $1.37 Billion | $7.32 Billion | -15.27pp |
| 2018-12-31 | 34.03% | $2.37 Billion | $6.96 Billion | +16.53pp |
| 2017-12-31 | 17.50% | $920.00 Million | $5.26 Billion | -1.75pp |
| 2016-12-31 | 19.25% | $824.21 Million | $4.28 Billion | +2.51pp |
| 2015-12-31 | 16.74% | $617.45 Million | $3.69 Billion | -4.30pp |
| 2014-12-31 | 21.04% | $702.22 Million | $3.34 Billion | +6.00pp |
| 2013-12-31 | 15.04% | $453.97 Million | $3.02 Billion | -20.67pp |
| 2012-12-31 | 35.71% | $916.22 Million | $2.57 Billion | -4.67pp |
| 2011-12-31 | 40.38% | $886.59 Million | $2.20 Billion | +5.29pp |
| 2010-12-31 | 35.09% | $645.34 Million | $1.84 Billion | -3.30pp |
| 2009-12-31 | 38.39% | $548.89 Million | $1.43 Billion | +15.65pp |
| 2008-12-31 | 22.73% | $313.05 Million | $1.38 Billion | +1.36pp |
| 2007-12-31 | 21.38% | $211.14 Million | $987.73 Million | -9.37pp |
| 2006-12-31 | 30.75% | $92.42 Million | $300.58 Million | -61.11pp |
| 2005-12-31 | 91.86% | $92.42 Million | $100.61 Million | +79.00pp |
| 2004-12-31 | 12.86% | $12.21 Million | $94.91 Million | -7.61pp |
| 2003-12-31 | 20.47% | $20.32 Million | $99.23 Million | -21.96pp |
| 2002-12-31 | 42.43% | $51.73 Million | $121.91 Million | -28.06pp |
| 2001-12-31 | 70.49% | $86.33 Million | $122.47 Million | +69.74pp |
| 2000-12-31 | 0.75% | $1.00 Million | $132.79 Million | -34.43pp |
| 1999-12-31 | 35.18% | $11.92 Million | $33.89 Million | -- |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more